Imidazopyridine-based fatty acid synthase inhibitors that show anti-HCV activity and in vivo target modulation

ACS Medicinal Chemistry Letters

Volumn 4, Issue 1, 2013, Pages 113-117

  Oslob, Johan D ^a   Johnson, Russell J ^a   Cai, Haiying ^a   Feng, Shirley Q ^a   Hu, Lily ^a   Kosaka, Yuko ^a   Lai, Julie ^a   Sivaraja, Mohanram ^a   Tep, Samnang ^a   Yang, Hanbiao ^a   Zaharia, Cristiana A ^a   Evanchik, Marc J ^a   McDowell, Robert S ^a  

^a 3 V Biosciences Inc   (United States)

Author keywords

antiviral; FASN; HCV; in vivo; inhibitor; reversible; structure activity relationship; target modulation

Indexed keywords

ANTIVIRUS AGENT; FATTY ACID SYNTHASE INHIBITOR; IMIDAZOPYRIDINE DERIVATIVE; TELAPREVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; HEPATITIS C VIRUS; IC 50; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; REPLICON; STRUCTURE ACTIVITY RELATION;

HEPATITIS C VIRUS; RATTUS;

EID: 84872341720     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300335r     Document Type: Article

References (31)

1. Chirala, S. S.; Wakil, S. J. Structure and function of animal fatty acid synthase Lipids 2004, 39 (11) 1045-1053
2. Liu, H.; Liu, J. Y.; Wu, X.; Zhang, J. T. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker Int. J. Biochem. Mol. Biol. 2010, 1 (1) 69-89
3. Kuhajda, F. P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology Nutrition 2000, 16 (3) 202-208
4. Menendez, J. A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis Nat. Rev. Cancer 2007, 7 (10) 763-777
5. Abramson, H. N. The lipogenesis pathway as a cancer target J. Med. Chem. 2011, 54 (16) 5615-5638
6. Menendez, J. A.; Vazquez-Martin, A.; Ortega, F. J.; Fernandez-Real, J. M. Fatty acid synthase: Association with insulin resistance, type 2 diabetes, and cancer Clin. Chem. 2009, 55 (3) 425-38
7. Wakil, S. J.; Abu-Elheiga, L. A. Fatty acid metabolism: target for metabolic syndrome J. Lipid Res. 2009, 50 (Suppl.) S138-S143
8. Wu, M.; Singh, S. B.; Wang, J.; Chung, C. C.; Salituro, G.; Karanam, B. V.; Lee, S. H.; Powles, M.; Ellsworth, K. P.; Lassman, M. E.; Miller, C.; Myers, R. W.; Tota, M. R.; Zhang, B. B.; Li, C. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (13) 5378-5383
9. Yang, W.; Hood, B. L.; Chadwick, S. L.; Liu, S.; Watkins, S. C.; Luo, G.; Conrads, T. P.; Wang, T. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production Hepatology 2008, 48 (5) 1396-1403
10. Melnikova, I. Hepatitis C-Pipeline update Nat. Rev. Drug Discovery 2011, 10 (2) 93-94
11. Lemon, S. M.; Walker, M. C.; Alter, M. J.; Yi, M. Hepatitis C Virus. In Fields Virology; Knipe, D. M.; Howley, P. M.; Griffin, D. E.; Lamb, R. A.; Martin, M. A.; Roizman, B.; Straus, S. E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2006; Vol. 1, pp 1253-1304.
12. Prussia, A.; Thepchatri, P.; Snyder, J. P.; Plemper, R. K. Systematic Approaches towards the Development of Host-Directed Antiviral Therapeutics Int. J. Mol. Sci. 2011, 12 (6) 4027-52
13. Schwegmann, A.; Brombacher, F. Host-directed drug targeting of factors hijacked by pathogens Sci. Signal 2008, 1 (29) re8
14. Flavin, R.; Peluso, S.; Nguyen, P. L.; Loda, M. Fatty acid synthase as a potential therapeutic target in cancer Future Oncol. 2010, 6 (4) 551-562
15. For a recent example of a novel inhibitor scaffold, see Abdel-Magid, A. F. Fatty Acid Synthase Inhibitors as Possible Treatment for Cancer. ACS Med. Chem. Lett. 2012, 3 (8), 612-613.
16. Kemble, G.; McDowell, R.; Moese, S.; Oslob, J. D.; Patick, A. K.; Yendluri, S.; Parsey, M. Potent Hepatitis C Antiviral Activity by Inhibiting Fatty Acid Synthase. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
17. Evanchik, M.; Cai, H.; Feng, Q. S.; Hu, L.; Johnson, R.; Kemble, G.; Kosaka, Y.; Lai, J.; Oslob, J. D.; Sivaraja, M.; Tep, S.; Yang, H.; Zaharia, C. A.; McDowell, R. TVB-2640, a Novel Anti-HCV Agent, Safely Causes Sustained Host-Target Inhibition In Vivo. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
18. Wallenius, L.; Butlin, R.; Kjellstedt, A.; Lofgren, L.; Oakes, N. A Novel Fatty Acid Synthase Inhibitor Suppresses De Novo Lipogenesis but induces Hepatic Steatosis, Dermatitis and does not enhance Insulin Sensitivity in Obese Zucker Rats. American Diabetes Association 68th Scientific Sessions, San Francisco, CA, 2008.
19. Pieper, H.; Linz, G.; Himmelsbach, F.; Austel, V.; Muller, T.; Weisenberger, J.; Guth, B. Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them. U.S. 5442064, 1995.
20. Sandström, J. Dynamic NMR Spectroscopy; Academic Press: London, New York, 1982.
21. Friebolin, H., Basic One- and Two-Dimensional NMR Spectroscopy; Wiley-VCH: Weinheim, New York, 1998.
22. Clayden, J.; Moran, W. J.; Edwards, P. J.; LaPlante, S. R. The challenge of atropisomerism in drug discovery Angew. Chem., Int. Ed. Engl. 2009, 48 (35) 6398-6401
23. Guile, S. D.; Bantick, J. R.; Cooper, M. E.; Donald, D. K.; Eyssade, C.; Ingall, A. H.; Lewis, R. J.; Martin, B. P.; Mohammed, R. T.; Potter, T. J.; Reynolds, R. H.; St-Gallay, S. A.; Wright, A. D. Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties J. Med. Chem. 2007, 50 (2) 254-263
24. LaPlante, S. R.; Edwards, P. J.; Fader, L. D.; Jakalian, A.; Hucke, O. Revealing atropisomer axial chirality in drug discovery ChemMedChem 2011, 6 (3) 505-513
25. Laplante, S. R.; Fader, L. D.; Fandrick, K. R.; Fandrick, D. R.; Hucke, O.; Kemper, R.; Miller, S. P.; Edwards, P. J. Assessing atropisomer axial chirality in drug discovery and development J. Med. Chem. 2011, 54 (20) 7005-7022
26. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6 (11) 881-90
27. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19 (15) 4406-4409
28. 50)-clogP.
29. Perola, E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 2010, 53 (7) 2986-2997
30. 50)/Mw × 1000.
31. Edwards, M. P.; Price, D. A. Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: Amsterdam, Boston, 2010; Vol. 45, Chapter 23, pp 380-391.